RAC MSPH - Atossa Therapeutics Quality Regulatory
| YAG2 Stock | 1.22 0.02 1.67% |
Insider
RAC MSPH is Quality Regulatory of Atossa Therapeutics
| Phone | 206 588 0256 |
| Web | https://www.atossatherapeutics.com |
Atossa Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.113) % which means that it has lost $0.113 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1833) %, meaning that it generated substantial loss on money invested by shareholders. Atossa Therapeutics' management efficiency ratios could be used to measure how well Atossa Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 14 records | INSIDER Age | ||
| Umar Qadri | NetSol Technologies | N/A | |
| Steve Shin | Amkor Technology | 60 | |
| BooAli FCA | NetSol Technologies | 48 | |
| Matt Glover | NetSol Technologies | N/A | |
| Roger CPA | NetSol Technologies | 58 | |
| Salim Ghauri | NetSol Technologies | 67 | |
| Farshad Haghighi | Amkor Technology | 60 | |
| Mark Rogers | Amkor Technology | 57 | |
| Jennifer Jue | Amkor Technology | N/A | |
| Megan Faust | Amkor Technology | 49 | |
| Susan Kim | Amkor Technology | 60 | |
| James Kim | Amkor Technology | 87 | |
| Giel Rutten | Amkor Technology | 66 | |
| Mike Liang | Amkor Technology | N/A | |
Management Performance
| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 |
Atossa Therapeutics Leadership Team
Elected by the shareholders, the Atossa Therapeutics' board of directors comprises two types of representatives: Atossa Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atossa. The board's role is to monitor Atossa Therapeutics' management team and ensure that shareholders' interests are well served. Atossa Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atossa Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Heather Rees, VP Accounting | ||
| FCAP MD, CEO Chairman | ||
| Delly PHR, VP HR | ||
| RAC MSPH, Quality Regulatory | ||
| Richard MD, Interim Officer | ||
| CPA Esq, Gen CFO |
Atossa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Atossa Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 | |||
| Current Valuation | (59.13 M) | |||
| Shares Outstanding | 126.62 M | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 20.65 % | |||
| Price To Book | 0.62 X | |||
| EBITDA | (20.5 M) | |||
| Net Income | (20.61 M) | |||
| Book Value Per Share | 0.97 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Atossa Stock Analysis
When running Atossa Therapeutics' price analysis, check to measure Atossa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Therapeutics is operating at the current time. Most of Atossa Therapeutics' value examination focuses on studying past and present price action to predict the probability of Atossa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Therapeutics' price. Additionally, you may evaluate how the addition of Atossa Therapeutics to your portfolios can decrease your overall portfolio volatility.